Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives
Top Cited Papers
- 1 July 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Drug Discovery
- Vol. 9 (7), 560-574
- https://doi.org/10.1038/nrd3115
Abstract
Advances in therapeutic strategies for Alzheimer's disease that lead to even small delays in onset and progression of the condition would significantly reduce the global burden of the disease. To effectively test compounds for Alzheimer's disease and bring therapy to individuals as early as possible there is an urgent need for collaboration between academic institutions, industry and regulatory organizations for the establishment of standards and networks for the identification and qualification of biological marker candidates. Biomarkers are needed to monitor drug safety, to identify individuals who are most likely to respond to specific treatments, to stratify presymptomatic patients and to quantify the benefits of treatments. Biomarkers that achieve these characteristics should enable objective business decisions in portfolio management and facilitate regulatory approval of new therapies.Keywords
This publication has 132 references indexed in Scilit:
- Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's diseaseNature Genetics, 2009
- Disclosure ofAPOEGenotype for Risk of Alzheimer's DiseaseThe New England Journal of Medicine, 2009
- Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjectsAnnals of Neurology, 2009
- Alzheimer’s disease risk variants show association with cerebrospinal fluid amyloid betaneurogenetics, 2008
- Phase 2 Safety Trial Targeting Amyloid β Production With a γ-Secretase Inhibitor in Alzheimer DiseaseArchives of Neurology, 2008
- The Alzheimer's disease neuroimaging initiative (ADNI): MRI methodsJournal of Magnetic Resonance Imaging, 2008
- A survey of genetic human cortical gene expressionNature Genetics, 2007
- N-Acetylaspartate in the CNS: From neurodiagnostics to neurobiologyProgress in Neurobiology, 2007
- Alzheimer's diseaseThe Lancet, 2006
- Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐BAnnals of Neurology, 2004